Flag of the European Union EU Clinical Trials Register Help

Clinical trials for RNA polymerase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    86 result(s) found for: RNA polymerase. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2012-001457-50 Sponsor Protocol Number: SIL-TH-01 Start Date*: 2012-05-23
    Sponsor Name:fUNDACIÓN iNVESTIGACIÓN HOSPITAL RAMÓN Y CAJAL
    Full Title: Study on the effect of intravenous silimaryn in the perioperative period of liver transplantation (before, during and after) for the prevention and prognosis of hepatitis C virus reinfection of the...
    Medical condition: Patients transplanted for chronic liver disease or hepatocarcinoma relating to C virus being replicated at the time of the OLT (orthotopic liver transplantation).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001224-33 Sponsor Protocol Number: COV-HCQ Start Date*: 2020-03-25
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19
    Medical condition: Acute coronavirus disease 2019
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10053983 Corona virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002458-66 Sponsor Protocol Number: AI443-113 Start Date*: 2013-12-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
    Medical condition: HEPATITIS C VIRUS
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10072848 Hepatitis C virus genotype 1 positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000640-24 Sponsor Protocol Number: NP25733 Start Date*: 2011-08-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of the HC...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002468-20 Sponsor Protocol Number: AI443-102 Start Date*: 2013-12-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C
    Medical condition: HEPATITIS C VIRUS
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10072848 Hepatitis C virus genotype 1 positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-008258-21 Sponsor Protocol Number: NV20536 eu Start Date*: 2009-03-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegas...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006604-11 Sponsor Protocol Number: NV19865 Start Date*: 2007-12-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys...
    Medical condition: Chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003329-89 Sponsor Protocol Number: AI467-003 Start Date*: 2012-04-03
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-...
    Medical condition: Human Immunodeficiency Virus type 1 (HIV-1) infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001739-35 Sponsor Protocol Number: SOFT-preOLT Start Date*: 2014-08-25
    Sponsor Name:Università di Modena e ReggioEmilia
    Full Title: An Open-Label Study to Explore the Clinical Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant in HIV-HCV infected pa...
    Medical condition: Individuals with HIV-HCV co-infection and end-stage liver disease, with an indication for liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10057212 Hepatitis viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022067-35 Sponsor Protocol Number: PP25213 Start Date*: 2011-02-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease Inhibitor (RO5190591/r, DNV/...
    Medical condition: Chronic Hepatitis C (CHC) Genotype 1 (Arms A and B) and Genotypes 1b and 4 (Arm C)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000533-22 Sponsor Protocol Number: VX-950-TiDP24-C216 Start Date*: 2008-11-14
    Sponsor Name:Tibotec BVBA
    Full Title: A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop...
    Medical condition: Chronic genotype 1 Hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) SE (Completed) FR (Completed) AT (Completed) IT (Completed) GB (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-018197-66 Sponsor Protocol Number: 1241.21 Start Date*: 2010-04-29
    Sponsor Name:Unilfarma, Lda.
    Full Title: Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with or without ribavirin for 4, 16, 24, 28 or 40 weeks in patients with chronic HCV genotype 1 infectio...
    Medical condition: chronic hepatitis C infection of genotype 1
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) FR (Completed) DE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-020033-14 Sponsor Protocol Number: CDEB025A2210 Start Date*: 2010-09-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicentre, randomized, double-blind, placebocontrolled, parallel-group phase II study on efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genotyp...
    Medical condition: Chronic Hepatitis C Genotype 1 patients
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) FR (Completed) ES (Completed) BE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001653-40 Sponsor Protocol Number: 64041575RSV2003 Start Date*: 2016-12-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Re...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000167-69 Sponsor Protocol Number: AIC649-02-II-01 Start Date*: 2021-06-30
    Sponsor Name:AiCuris Anti-Infective Cures AG
    Full Title: A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AIC649 in the treatment of otherwise healthy subjects with asymptomatic or mildly symptomatic SARS-CoV-2 ...
    Medical condition: asymptomatic or mildly symptomatic SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084467 Asymptomatic SARS-CoV-2 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001026-22 Sponsor Protocol Number: 1813T0835 Start Date*: 2021-03-05
    Sponsor Name:Shionogi & Co., Ltd.
    Full Title: An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Baloxavir Marboxil 2% Granules after Administration of a Single Dose to Otherwise Healthy Pediatric Patient...
    Medical condition: Influenza
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019585-90 Sponsor Protocol Number: WV21913 Start Date*: 2011-05-05
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2004-001657-29 Sponsor Protocol Number: TMC125-C227 Start Date*: 2006-07-05
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: A Phase II, randomized, active controlled, open label trial to investigate the efficacy and tolerability of TMC125 in HIV-1 infected subjects, who are PI-naïve and with documented genotypic evidenc...
    Medical condition: HIV-1 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-004527-31 Sponsor Protocol Number: GS-US-196-0103 Start Date*: 2008-12-12
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and...
    Medical condition: Genotype-1 Chronic Hepatitis C Virus (HCV) Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005759-18 Sponsor Protocol Number: CV43043 Start Date*: 2021-05-10
    Sponsor Name:F. Hoffmann La Roche Ltd.
    Full Title: A MULTICENTER, PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OUTPATIENT STUDY TO EVALUATE THE EFFICACY, SAFETY, AND ANTIVIRAL ACTIVITY OF RO7496998 AT-527 IN PATIENTS WITH MILD OR MODERAT...
    Medical condition: Mild to Moderate coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) DK (Prematurely Ended) FR (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:15:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA